Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.arvinas.com
Arvinas News Releases
Get the latest updates from Arvinas News Releases directly as they happen.
Follow now 50 followers
Latest posts
Last updated 9 days ago
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
9 days ago
– Reported positive topline results from the Phase 3 VERITAC-2 trial that...
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
12 days ago
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq...
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
12 days ago
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination...
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
17 days ago
– Oral presentation will serve as first presentation of detailed results from...
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
19 days ago
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader...
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
about 1 month ago
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant...
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
about 1 month ago
– Company to highlight first-in-human data from healthy volunteers in both the...
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
about 2 months ago
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population...
Arvinas to Participate in Upcoming Investor Conferences
2 months ago
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq...
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3 months ago
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial...
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
3 months ago
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq...
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
4 months ago
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib...